Trial Profile
Expression of Inflammatory Mediators in Induced Sputum: A Potential Biomarker of Drug Response in COPD
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 22 Jul 2011 New trial record